SHPH

Company Overview — What Does Shuttle Pharmaceuticals Holdings, Inc. Do?

Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the late effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment, or in combination with surgery, chemotherapy and immunotherapy. We currently have no FDA approved products and we have not yet applied for a new drug application. To date, we have been funded by investments from private investors and government contracts obtained from the National Institutes of Health (NIH) for performing research. We have no product revenue and our independent auditors, in their report dated June 3, 2022, expressed doubt about our ability to continue as a going concern. Historically, the major advances in radiation oncology have focused on improving technology to increase the amount of radiation that can be administered to a tumor without damaging adjacent, normal tissues. Examples of other such technologies include intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), stereotactic radiosurgery (SRS) and proton therapy – the backbones of state-of-the-art RT. All offer improvements in physical radiation dose shaping. The basic principle underlying the effectiveness of RT for curing cancers lies in the differential cancer cell kill achieved in tumors, as compared to the effects of RT on the normal surrounding tissues, which is achieved by delivery of highly conformal RT doses – in other words, delivery of high-dose to volumes that are shaped to conform to the target cancers while minimizing the dose to surrounding normal tissues. The treated volumes frequently include sensitive normal tissues, thereby limiting the magnitudes of the prescribed RT doses. We suggest that technological innovations to define tumor volumes and shape radiation delivery have reached an effectiveness plateau and that further improvements in RT outcomes will require pharmacological and immunological approaches to sensitize cancers, protect normal tissues and engage the immune system. At present, the drugs being used for sensitizing cancers to RT are chemotherapeutic agents possessing radiation sensitizing properties as secondary effects. With the exception of Cituximab, a growth factor targeting monoclonal antibody biologic, all other drugs used as radiation sensitizers are used “off-label” to address the clinical need for radiation sensitizers. For example, certain chemotherapeutic agents, such as 5-fluorouracil, capecitabine and cis-platinum, are approved as single agents for cancer treatment, but are used “off-label” as radiation sensitizers in combination with RT. Treatments with such agents are associated with inherent toxicities associated with the drug’s primary, single-agent mechanisms of action. Shuttle Pharma’s platform of sensitizers offers a pipeline of product candidates designed to address the urgent clinical need and the current limitations of using “off-label” drugs with potential new sensitizer agents. Our pipeline includes Ropidoxuridine, our lead clinical sensitizer drug candidate, to sensitize rapidly growing cancer cells and selective histone deacetylase (HDAC) inhibitors to sensitize cancer cells and stimulate the immune system. Our novel technologies will be tested in combinations with radiation therapies (conventional X-ray and proton radiation therapies) and in combinations with immune-therapies. To date, Ropidoxuridine has completed a Phase I clinical trial. Our HDAC inhibitor platform drug candidates have been tested in preclinical models of solid tumor cancers. Ropidoxuridine and the selective HDAC6 inhibitor SP-2-225 are the clinical and preclinical candidate drug products we propose to develop using funding from this offering. Our intellectual property for Ropidoxuridine includes novel formulations that show improved drug bioavailability (in a preclinical animal model) and for sensitizing cancers to proton and to conventional radiation therapies. Our HDAC inhibitor intellectual property includes new patent applications and granted patents for composition of matter and methods of use for treating cancers with HDAC inhibitors in combinations with radiation therapy. To date, we have obtained funding for our research from private investors and Small Business Innovation Research (“SBIR”) contracts obtained through the National Institutes of Health (“NIH”) to support the development of the radiation sensitizer Ropidoxuridine in a Phase I clinical trial. We have also received awards for Phase I and II SBIR contracts for development of human cell cultures for health disparities studies and predictive biomarkers of radiation late effects through the NIH’s National Cancer Institute. The completed Phase I and II funded discovery work performed to establish “Cell-based Models for Prostate Cancer Health Disparity Research” and to develop “Predictive Biomarkers of Prostate Cancer Sensitivity for Radiation Late Effects” enables Shuttle Pharma to apply for NIH SBIR Phase II funding to develop these products for advancing basic science and clinical research. The Company was formed as a limited liability company in the state of Maryland in December 2012 and was converted to a C corporation, Shuttle Pharmaceuticals, Inc. (“Shuttle”), in August of 2016. In June 2018, Shuttle completed a share exchange with Shuttle Pharma Acquisition Corp. Inc. (“Acquisition Corp.”), pursuant to which Shuttle Pharmaceuticals, Inc. became a subsidiary of Acquisition Corp. and we subsequently changed the name of Acquisition Corp. to Shuttle Pharmaceuticals Holdings, Inc. Our executive offices are located at 1 Research Court, Suite 450, Rockville, Maryland. Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Anatoly Dritschilo and employs approximately 5 people. With a market capitalization of $4M, SHPH is one of the notable companies in the Healthcare sector.

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Stock Rating — Avoid (April 2026)

As of April 2026, Shuttle Pharmaceuticals Holdings, Inc. receives a Avoid rating with a composite score of 19.5/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.SHPH ranks #4,389 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Shuttle Pharmaceuticals Holdings, Inc. ranks #819 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SHPH Stock Price and 52-Week Range

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) currently trades at $0.70. The stock lost $0.03 (3.5%) in the most recent trading session. The 52-week high for SHPH is $5.59, which means the stock is currently trading -87.5% from its annual peak. The 52-week low is $0.12, putting the stock 461.3% above its annual trough. Recent trading volume was 83K shares, suggesting relatively thin trading activity.

Is SHPH Overvalued or Undervalued? — Valuation Analysis

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.85x, versus the sector average of 2.75x.

At current multiples, Shuttle Pharmaceuticals Holdings, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Shuttle Pharmaceuticals Holdings, Inc. Profitability — ROE, Margins, and Quality Score

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -569.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -122.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SHPH Debt, Balance Sheet, and Financial Health

Shuttle Pharmaceuticals Holdings, Inc. has a debt-to-equity ratio of 365.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 0.06x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $0. Cash and equivalents stand at $2M.

SHPH has a beta of 6.10, meaning it is more volatile than the broader market — a $10,000 investment in SHPH would be expected to move 510.0% more than the S&P 500 on any given day. The stability factor score for Shuttle Pharmaceuticals Holdings, Inc. is 4/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Shuttle Pharmaceuticals Holdings, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Shuttle Pharmaceuticals Holdings, Inc. reported revenue of $0 and earnings per share (EPS) of $-7.16. Net income for the quarter was $-13M. Operating income came in at $-12M.

In FY 2025, Shuttle Pharmaceuticals Holdings, Inc. reported revenue of $-10M and earnings per share (EPS) of $-7.16. Net income for the quarter was $-12M. Revenue grew -70.1% year-over-year compared to FY 2024. Operating income came in at $-12M.

In Q3 2025, Shuttle Pharmaceuticals Holdings, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.05. Net income for the quarter was $-2M. Operating income came in at $-2M.

In Q2 2025, Shuttle Pharmaceuticals Holdings, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.29. Net income for the quarter was $-4M. Operating income came in at $-4M.

Over the past 8 quarters, Shuttle Pharmaceuticals Holdings, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing SHPH stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SHPH Dividend Yield and Income Analysis

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SHPH Momentum and Technical Analysis Profile

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has a momentum factor score of 43/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 17/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

SHPH vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Shuttle Pharmaceuticals Holdings, Inc. (SHPH) ranks #819 out of 838 stocks based on the Blank Capital composite score. This places SHPH in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SHPH against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SHPH vs S&P 500 (SPY) comparison to assess how Shuttle Pharmaceuticals Holdings, Inc. stacks up against the broader market across all factor dimensions.

SHPH Next Earnings Date

No upcoming earnings date has been announced for Shuttle Pharmaceuticals Holdings, Inc. (SHPH) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SHPH? — Investment Thesis Summary

The quantitative profile for Shuttle Pharmaceuticals Holdings, Inc. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. High volatility (stability score 4/100) increases portfolio risk.

In summary, Shuttle Pharmaceuticals Holdings, Inc. (SHPH) earns a Avoid rating with a composite score of 19.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SHPH stock.

Related Resources for SHPH Investors

Explore more research and tools: SHPH vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SHPH head-to-head with peers: SHPH vs AZN, SHPH vs SLGL, SHPH vs VMD.